Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Morphotek evaluates MORAb-004 in new phase II trial

April 18, 2012

Promising first clinical results reported on Affimed TandAb

April 13, 2012

Biovest to file marketing application in Canada

April 11, 2012

First-in-class cancer immunotherapy well tolerated in phase I trial

April 10, 2012

Roche reports topline data from phase III EMILIA trial

April 2, 2012

New encapsulated stem cell therapy induces cell death in gliomas

March 29, 2012

Morphotek completes enrollment in farletuzumab study

March 28, 2012

Biotest reports promising preclinical data on BT-062

March 23, 2012

Milestone reached in OncoTherapy Science/Shionogi collaboration

March 21, 2012

Patrys reports on phase I PAT-SM6 trial

March 21, 2012

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...